Neuromodulation Failed to Lower Blood Pressure
A clinical trial found that transcutaneous stimulation did not significantly reduce systolic blood pressure.
Updated on Oct. 6, 2026 in Stroke
Live Poll
Do you trust non-invasive medical devices to help manage your long-term blood pressure?
A phase 2a clinical trial has found that transcutaneous autonomic neuromodulation did not significantly reduce daytime systolic blood pressure in patients with uncontrolled hypertension. The findings suggest the treatment was no more effective than a sham device for the overall study population.
Why it matters
While the overall results showed no benefit, the study identified a potential reduction in blood pressure for a specific subgroup of patients. This points to a need for further research to determine if this therapy could eventually serve as a targeted intervention for those with higher baseline levels.
The study involved 63 adults with a mean age of 47.2 years and mean baseline ambulatory blood pressure of 150/95 mm Hg. Participants achieved 100% median adherence using electrode clips for 30 minutes daily.
The players
Hypertension
This is a peer-reviewed medical journal that publishes original research regarding the causes, prevention, and treatment of high blood pressure.
The details
Participants in the London-based study maintained their standard antihypertensive medication while using electrode clips in front of each ear canal to deliver stimulation. Despite perfect treatment adherence, the active group did not outperform the sham group, though those starting with systolic blood pressure of 160 mm Hg or higher saw a 12.73 mm Hg reduction.
Timeline
September 28, 2026: The study results were published in the journal Hypertension.
3 months: Researchers measured primary efficacy endpoint changes for all participants.
The Big Picture
This study follows a pattern set by broader transcutaneous autonomic neuromodulation research into non-invasive interventions for chronic physiological conditions. These findings mark a departure from initial expectations by failing to demonstrate significant efficacy in a general hypertensive population.
Patients with uncontrolled hypertension should continue relying on their established medication regimens as prescribed by their physicians. The experimental neuromodulation device is not currently a proven alternative or supplemental treatment for routine blood pressure management.
The takeaway
This trial highlights the complexity of managing hypertension with non-invasive electrical stimulation technologies. Patients should maintain their current treatment plans until further studies identify specific populations that may truly benefit from this approach.
Further reading
For more information on cardiovascular health, visit the Stroke section.
Live Poll
Do you trust non-invasive medical devices to help manage your long-term blood pressure?
